Pier 88 Investment Partners’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $327K | Sell |
12,700
-52,100
| -80% | -$1.07M | 0.08% | 77 |
|
|
2026
Q1 | $1.24M | Sell |
64,800
-3,400
| -5% | -$67.7K | 0.32% | 39 |
|
|
2025
Q4 | $1.13M | Buy |
68,200
+760
| +1% | +$12.8K | 0.25% | 47 |
|
|
2025
Q3 | $979K | Buy |
67,440
+10,290
| +18% | +$148K | 0.18% | 60 |
|
|
2025
Q2 | $800K | Buy |
57,150
+12,240
| +27% | +$172K | 0.15% | 65 |
|
|
2025
Q1 | $611K | Sell |
44,910
-500
| -1% | -$9.58K | 0.12% | 80 |
|
|
2024
Q4 | $925K | Sell |
45,410
-13,760
| -23% | -$352K | 0.18% | 56 |
|
|
2024
Q3 | $1.72M | Sell |
59,170
-10,200
| -15% | -$253K | 0.38% | 36 |
|
|
2024
Q2 | $1.61M | Buy |
69,370
+29,400
| +74% | +$564K | 0.36% | 42 |
|
|
2024
Q1 | $820K | Sell |
39,970
-5,270
| -12% | -$99K | 0.2% | 46 |
|
|
2023
Q4 | $971K | Sell |
45,240
-5,460
| -11% | -$108K | 0.24% | 54 |
|
|
2023
Q3 | $1.05M | Buy |
50,700
+3,020
| +6% | +$76.6K | 0.26% | 63 |
|
|
2023
Q2 | $1.41M | Buy |
47,680
+4,840
| +11% | +$136K | 0.35% | 51 |
|
|
2023
Q1 | $987K | Buy |
42,840
+7,600
| +22% | +$209K | 0.24% | 55 |
|
|
2022
Q4 | $980K | Buy |
35,240
+23,150
| +191% | +$689K | 0.24% | 54 |
|
|
2022
Q3 | $371K | Sell |
12,090
-990
| -8% | -$32.2K | 0.09% | 79 |
|
|
2022
Q2 | $385K | Buy |
13,080
+13,070
| +130,700% | +$342K | 0.09% | 85 |
|
|
2022
Q1 | $0 | Sell |
10
-33,070
| -100% | -$1.14M | ﹤0.01% | 90 |
|
|
2021
Q4 | $1.48M | Buy |
33,080
+14,200
| +75% | +$673K | 0.31% | 64 |
|
|
2021
Q3 | $952K | Buy |
18,880
+4,760
| +34% | +$268K | 0.29% | 73 |
|
|
2021
Q2 | $1.11M | Buy |
14,120
+6,560
| +87% | +$406K | 0.32% | 74 |
|
|
2021
Q1 | $432K | Sell |
7,560
-5,265
| -41% | -$352K | 0.15% | 98 |
|
|
2020
Q4 | $1.07M | Sell |
12,825
-22,970
| -64% | -$1.39M | 0.35% | 53 |
|
|
2020
Q3 | $1.28M | Sell |
35,795
-16,514
| -32% | -$497K | 0.39% | 53 |
|
|
2020
Q2 | $1.26M | Buy |
52,309
+4,609
| +10% | +$108K | 0.36% | 69 |
|
|
2020
Q1 | $835K | Buy |
47,700
+5,700
| +14% | +$119K | 0.3% | 57 |
|
|
2019
Q4 | $732K | Buy |
42,000
+1,390
| +3% | +$23.1K | 0.29% | 47 |
|
|
2019
Q3 | $622K | Buy |
40,610
+12,960
| +47% | +$248K | 0.24% | 65 |
|
|
2019
Q2 | $574K | Sell |
27,650
-8,280
| -23% | -$186K | 0.24% | 70 |
|
|
2019
Q1 | $834K | Buy |
35,930
+9,800
| +38% | +$205K | 0.38% | 48 |
|
|
2018
Q4 | $540K | Sell |
26,130
-11,800
| -31% | -$214K | 0.27% | 52 |
|
|
2018
Q3 | $825K | Buy |
+37,930
| New | +$627K | 0.36% | 41 |
|
Other funds holding DNLI
Pier 88 Investment Partners's DNLI Position: Q2 2026 in Review
Pier 88 Investment Partners reduced its Denali Therapeutics (DNLI) stake by 80% in Q2 2026, selling an estimated $1.07M and leaving 12,700 shares worth $327K. The position accounts for 0.08% of the portfolio, ranked #77.
Pier 88 Investment Partners first reported a position in DNLI in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.72M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Pier 88 Investment Partners held 12,700 shares of Denali Therapeutics worth $327K as of Q2 2026.
- Pier 88 Investment Partners sold 52,100 Denali Therapeutics shares in Q2 2026, an estimated $1.07M.
- Denali Therapeutics made up 0.08% of Pier 88 Investment Partners's portfolio in Q2 2026, its #77 holding.
- Pier 88 Investment Partners first reported a position in Denali Therapeutics in Q3 2018 and has held it in 32 quarters since.
- Pier 88 Investment Partners's Denali Therapeutics position peaked at $1.72M in Q3 2024.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Pier 88 Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.